Lynch syndrome is a genetic disorder that greatly increases risk for colorectal and other cancers, although it is underdiagnosed. Prediction of MLH1, MSH2, and MSH6 (PREMM 1,2,6 ) is a webbased tool that analyzes individuals' personal/family histories of cancer to quantify their likelihood of carrying a germline mutation associated with Lynch syndrome. We investigated the feasibility of systematic risk assessment for Lynch syndrome in a community gastroenterology practice using a patient-completed version of PREMM 1,2,6 .
L ynch syndrome (LS) is the most common hereditary colorectal cancer (CRC) syndrome, accounting for 2% to 4% of all cases of CRC. [1] [2] [3] [4] [5] LS is caused by germline mutations in the DNA mismatch repair genes (MLH1, MSH2, MSH6, and PMS2) and EPCAM and confers a high lifetime risk of CRC (up to 74%), endometrial cancer (up to 71%), as well as increased risks of cancers of the ovaries, stomach, small intestine, pancreas, urinary tract, and other sites. 6 However, the lack of a systematic way to identify LS patients leaves a significant number of individuals who are at a tremendously high risk of having cancer without being aware of their risk. In fact, it is estimated that approximately 1 million individuals in the United States have LS, but that the vast majority are unaware of their diagnosis. 7 Diagnosing LS allows for the opportunity to implement appropriate enhanced cancer surveillance (eg, colonoscopies every 1-2 years), prophylactic surgery (eg, risk-reducing hysterectomy and salpingo-oophorectomy), and chemoprevention for mutation carriers, as well as predictive germline testing of at-risk family members. 6, 8 Screening of patients who may have a hereditary cancer syndrome is recommended by the National Comprehensive Cancer Network and the US Multi-Society Task Force on Colorectal Cancer. 6, 9, 10 Screening efforts should address patients with cancers that may be related to mutations in LS genes, as well as unaffected patients who may be at risk for hereditary cancers as a result of family history.
There are several approaches to LS risk assessment, such as clinical criteria, tumor testing, and prediction models. Although each method has its benefits, clinical criteria are complicated, difficult to recall, and may miss 30% to 50% of mutation carriers. 11, 12 Disadvantages to the tumor-testing approach include the fact that it is limited to patients affected by cancer and uptake is variable despite recommendations for universal tumor testing. 1 Although universal tumor screening recently was shown to be well accepted by patients, 13 this approach also only identifies LS in patients after cancer has developed. A universal screening approach that can identify LS in patients based on their family history offers a means to intervene before cancer develops. One way of offering universal screening is through the prediction model approach, which includes one of several risk-assessment algorithms that have been developed to calculate the likelihood of LS in individuals based on personal and family history. These include the Prediction of MLH1 and MSH2 (PREMM 1,2 ) model, 14 which was updated to improve predictive capacity by including MSH6 in the PREMM 1,2,6 model. 15 This tool incorporates personal and family history information to estimate the likelihood that a patient will have a mutation in one of these genes. 14, 15 Current national guidelines recommend consideration of genetic testing for LS in patients who score a 5% or higher risk on any of 3 existing LS prediction models, including PREMM 1,2,6 . 6, 9, 10 The performance of risk-assessment models such as PREMM 1, 2, 6 is dependent on the accuracy of the input of family history; however, clinical ascertainment of family histories can be difficult owing to a lack of standardized tools for collecting and assessing this information. 11, 12 Recent studies have shown that even when family history information is collected, the data often are limited to first-degree relatives or certain cancer types. 16 Risk-assessment models offer a standardized, validated, and effective approach to LS screening and genetic testing. Our recently developed PREMM 1,2,6 providerbased questionnaire has helped health care providers identify individuals at high risk for LS based on family history so that appropriate genetic testing and screening measures can be administered. In addition, the assessment of unaffected individuals who score 5% or higher with PREMM 1,2,6 may be cost effective. 17 However, there has been no report on systematic risk assessment, counseling, and genetic testing in a community-based medical practice setting through which patients are identified, screened, tested, and counseled for LS. Moreover, there are minimal data regarding the feasibility of patient-administered tools for the LS risk assessment. The aim of this study was to implement a systematic risk-assessment process to screen all individuals presenting to a gastroenterology practice for Lynch syndrome using PREMM 1, 2, 6 and to assess the feasibility of providing routine genetic evaluation, counseling, and testing based on a self-administered questionnaire.
Methods

Study Design and Participants
This was a prospective, single-arm, intervention study conducted in a community-based gastroenterology practice. Patients were recruited in the office and ambulatory endoscopy center at Monterey Bay Gastroenterology Consultants, Inc. This practice consists of 10 board-certified gastroenterologists and 1 nurse practitioner who service a population of approximately 200,000 people. The total study duration was 8 months and included a 60-day initiation period (May 1-June 30, 2013), and a 6-month study period (July 1-December 31, 2013). Implementation of the new, office-wide, genetic risk assessment process during the initiation period started with training all relevant staff, including providers, nurses, medical assistants, and scheduling and intake personnel. This included recognition of hereditary cancer syndromes based on personal and family history of cancer and training in study process integration. The process implemented was designed to minimize disruptions to practice efficiency while adequately addressing patient screening, counseling, and genetic testing for LS.
During the initiation period, a nonconsecutive cohort of participants was recruited without any specific preselection for high-risk features (eg, personal or family history of LS-associated cancers). During the study period, a consecutive cohort of potentially eligible subjects was approached for participation. Patients potentially were eligible to participate in this study if they were 18 years of age or older and were willing to complete the family cancer history screening questions. Patients who were unable to speak English, were pregnant, previously had undergone LS genetic testing, had 10 or more colorectal adenomatous polyps, or were unable to provide informed consent were excluded.
Patients who met the eligibility criteria underwent a standardized screening process to assess their risk for LS. At the initial telephone encounter to schedule the office or endoscopy visit, the patients were advised to obtain a family history of colorectal, uterine, and other LS-associated cancers. This information also was requested in mailings of registration materials and a routine family cancer history questionnaire and during the routine confirmation telephone call before their office visit or ambulatory endoscopy center encounter for endoscopic procedures. Upon arrival to the office or endoscopy center, patients were asked to complete a modified version of the PREMM 1,2,6 risk assessment tool. Because the current version of the web-based PREMM 1,2,6 model was designed to be completed by health care providers, the model was adapted and offered to eligible patients on tablet computers as a selfadministered questionnaire (Figure 1 ) because this would improve the efficacy in integrating genetic risk assessment into the practice's busy flow and high volume. Office staff provided patients with any assistance in completing the PREMM 1,2,6 assessment as needed and physicians reviewed each of their patient's generated PREMM 1,2,6 score ( Figure 2 ) during the office or endoscopy visit as part of the family history evaluation. Patients with a provider-verified PREMM 1,2,6 score of 5% or higher obtained during an office visit watched a 4-minute educational video on LS, received pretest genetic counseling by their gastroenterology physician in accordance with professional society guidelines, 18 and were offered genetic testing. Endoscopy center patients with a PREMM 1,2,6 score of 5% or higher were scheduled for a subsequent office visit for pretest genetic counseling and testing.
Patients who pursued genetic testing provided written informed consent before testing, per standard clinical practice. The medical assistants, nurse practitioner, and/ or physicians collected buccal mucosa and/or blood specimens from individuals who consented to genetic testing. Germline DNA was extracted from collected samples and underwent sequencing and large rearrangement analysis for the 5 genes underlying LS (MLH1, MSH2, MSH6, PMS2, and EPCAM) at a commercial laboratory (Myriad Genetic Laboratories, Inc, Salt Lake City, UT). Germline sequencing and rearrangement analysis of MUTYH also was performed as an exploratory analysis.
Patients whose genetic testing identified a pathogenic germline mismatch repair (MMR) gene mutation were seen by their gastroenterology provider for a 20-to 30-minute post-test office visit, at which time recommendations were made regarding appropriate LS-related screening interventions, plus the need for at-risk family members to undergo testing. Such individuals typically were followed up longitudinally by the practice for their ongoing gastroenterological care. Patients who underwent genetic testing completed a survey about the genetic risk evaluation and process after receiving their test results. Providers completed a separate survey at the end of the study period to evaluate the implementation and procedures related to the integration of the new genetic risk assessment process into routine practice. Patients and providers reported on their experience using a 5-point Likert scale. During the initiation period, the total number of individuals assessed and the number of genetic tests ordered was captured. During the study period, patient demographics, PREMM 1,2,6 scores, genetic testing results, and survey results on postprocess metrics were recorded. This study was approved by the Western Institutional Review Board (20121612). 
Results
Patient Participation and Demographics
During the 6-month study period, 5287 unique patients were evaluated during office or endoscopy visits, of whom 3134 (59%) potentially were eligible and agreed to use the self-administered PREMM 1,2,6 risk assessment tool. Of these, 177 of 3134 (5.6%; 95% confidence interval [CI], 4.9%-6.5%) had PREMM 1,2,6 scores of 5% or higher, watched a 4-minute educational video on LS, underwent genetic education and counseling by their physician, and were offered germline genetic testing. A total of 146 of 177 (82.5%; 95% CI, 75.9%-87.6%) individuals with PREMM 1,2,6 scores of 5% or higher consented to proceed with germline testing. Participants' reasons for declining germline testing were not collected. Patient demographic data, personal/family history of cancer(s), and the mean and median PREMM 1,2,6 scores for the 146 patients who underwent genetic testing during the study period are shown in Table 1 .
Of the 146 participants who consented to germline LS testing, 76 (52.1%) reported a personal history of cancer, including 22 with CRC (15.1%), 21 with endometrial cancer (14.4%), and 13 (8.9%) with a personal history of multiple cancers. A total of 130 of 146 (89.0%) participants undergoing LS testing reported a family history of cancer in 1 or more first-or second-degree relatives, including 84 (57.5%) with a family history of CRC and 71 (48.6%) with a family history of endometrial cancer. The median PREMM 1,2,6 score among the 146 participants who underwent LS genetic testing was 7.8% (range, 5.0%-93.2%).
Genetic Testing Results
In addition to the 146 participants who pursued genetic testing during the study period, 28 individuals also underwent testing during the initiation period (total N ¼ 174). Among all individuals tested, pathogenic MMR gene mutations were detected in 6 of 174 (3.5%; 95% CI, 1.4%-7.7%) subjects (Table 2) , including 3 of 146 (2.1%; 95% CI, 0.5%-6.4%) during the study period and 3 of 28 (10.7%; 95% CI, 2.8%-29.4%) during the initiation period. Five of 6 (83.3%) LS carriers had personal/family histories fulfilling Amsterdam II criteria. 6 Overall, 19 of 174 (10.9%; 95% CI, 6.9%-16.8%) participants had a germline MMR variant of uncertain significance identified. No participants were found to carry biallelic MUTYH mutations, although 3 of 174 (1.7%) were found to have monoallelic MUTYH mutations, and 4 of 174 (2.3%) were found to have a MUTYH variant of uncertain significance.
Patient Survey Results
Of the 146 patients who underwent genetic testing during the study period, 1 patient was lost to follow-up evaluation and the remaining 145 patients completed a survey after receiving their test results to assess their experience with the genetic risk assessment process, including genetic counseling and testing. This survey examined patient preparedness for their appointment and understanding of the information provided during care. The complete survey questions and responses are summarized in Table 3 . The data show that 83.5% of respondents thought the survey before the appointment prepared them to answer questions regarding personal and family history. In addition, 84.1% of respondents believed the information they provided was complete. A total of 98.6% of respondents understood the information given to them by their providers regarding genetic testing and 95.1% of respondents had enough time to discuss their questions regarding hereditary cancer syndromes and genetic testing.
The survey also assessed respondents' interpretation of the use of their personal and family cancer histories. Respondents had the option of selecting more than one option for why they believed their physician wanted them to receive genetic testing. The most common reasons respondents believed they were recommended for genetic testing were their personal (47.6%) and family (84.8%) history of cancer, and 84.1% of respondents believed this information was used to impact their care.
Provider Survey Results
All providers completed a survey at the end of the study about the process to assess the efficacy of and satisfaction with the implementation process, and explore the impact of genetic risk assessment and testing on subsequent medical decision making. The survey was completed by all 10 gastroenterologists and the 1 nurse practitioner who participated (Table 4 ). All providers reported that patients provided enough family information to complete the genetic risk assessment for LS using PREMM 1,2,6 and that PREMM 1,2,6 was an adequate tool for identifying patients appropriate for genetic testing. In addition, 90.9% of providers had enough time to answer patient questions regarding hereditary colorectal cancer syndromes and genetic testing and all providers indicated that they will continue to use this process to screen and test patients at risk for Lynch syndrome. A total of 81.8% of providers reported that their use of personal and family cancer history assessment would improve care for patients who underwent genetic testing, even for patients who tested negative for a germline mutation. Likewise, 81.8% of providers reported changing their treatment and medical management decisions based on the genetic testing information for patients found to carry a pathogenic LS gene mutation. All providers responded that they were overall satisfied with the incorporation of LS risk assessment and genetic testing into their practice.
Discussion
The results of this study suggest that routine, largescale, genetic risk assessment for LS is possible through the implementation of a standardized streamlined approach to collect and assess specific and relevant patient and family histories of cancer directly from patients. Although LS has been a recognized condition for more than a hundred years, identification of affected patients has remained a challenge. In recent years, there has been much progress made in implementation of universal tumor testing for microsatellite instability in patients with colorectal cancer. Restricting LS screening to patients with cancer, however, misses an opportunity to identify patients who are mutation carriers but in whom cancer has not yet developed and thus have the most to gain from prevention strategies.
With the inherent overload of medical practices and provider schedules, a tool completed by patients can alleviate some of the administrative burden on medical practices as well as empower the patient to determine his/her own risk and become an active participant in the risk assessment process. Community gastroenterology practices do not typically screen for LS, although screening in these practices could identify a large percentage of the at-risk population. This study demonstrated the ease of use of the PREMM 1,2,6 questionnaire among both patients and providers, and its ability to be implemented readily in community-based practices.
Integration of routine genetic cancer risk assessment and stratification relied heavily on patient preparedness in knowing their family cancer history before their inperson evaluation, and the ability to provide genetic education and counseling efficiently and effectively to those patients eligible for genetic testing based on PREMM 1,2,6 scores of 5% or higher. Only 5.6% (177 of 3134) of all individuals assessed in this busy practice were identified as needing genetic counseling and testing, which did not burden the practice's system in providing effective clinical evaluation and care in general gastroenterology. Providers reported that the operations of the practice and patient flow were not impacted significantly by the newly introduced genetic risk assessment process once the systems were implemented and that they had enough time to counsel patients adequately about genetic testing. All providers reported that they would continue to use PREMM 1, 2, 6 for LS screening beyond the study period and, indeed, use of PREMM 1,2,6 in this practice group has continued since this time. Although precise usage data have not been collected, the study's practitioners report having gradually moved away from universally applying PREMM 1,2,6 , particularly for evaluating patients lacking any personal/family history of LS-associated cancer, and instead routinely are using it to assess those with concerning or equivocal personal/family cancer histories. Because a PREMM 1,2,6 score of 5% or higher is an established criterion for germline LS testing in various national guidelines 6, 19 used to determine insurance coverage by payers, it remains quite feasible for such patients to pursue genetic testing even with cessation of the financial support provided by the study.
In our study, an informational video specifically dedicated to LS was used as an educational tool targeted to those individuals deemed at increased risk by PREMM 1, 2, 6 given their score of 5% or higher, followed by additional counseling by their provider. Ninety-eight percent of subjects who underwent genetic testing in this study reported being able to understand the information provided to them regarding hereditary cancer and genetic testing and 85% believed that their personal and family cancer history had an impact on their clinical care. Furthermore, the majority of patients undergoing testing understood that their family history of cancer increased their risk of an inherited cancer syndrome and was the primary indication for genetic testing.
There were a number of potential limitations related to this study. Patients completed a modified version of the PREMM 1,2,6 model, which was created specifically for use by patients and a lay audience (nonmedical providers) and results using such an approach have not been compared with those obtained by health care providers, such as certified genetic counselors, who traditionally assess familial risk through pedigree analysis. Although the absence of involvement by certified genetic counselors was a potential limitation of this study, this does represent a real-world issue for many community practices, particularly those within geographic areas where genetic counseling services are Ages at diagnosis were not available (presumed to be 75 years old, for the purposes of PREMM 1,2,6 score calculation).
scarce. For instance, at the time of this study, there were no cancer genetic counselors practicing within Monterey County, California. Although some payers have adopted policies that insurance coverage will be considered only for a genetic test that is ordered by a board-certified genetic counselor or medical geneticist, the 2015 American Society of Clinical Oncology Policy Statement Update on genetic testing for inherited cancer risk 18 specifically recommends against such mandates, arguing that they inherently limit patient access to critical genetic testing services. Given that the objective of this study was to assess the feasibility of applying PREMM 1,2,6 in routine clinical practice, germline testing was offered only to patients whose PREMM 1,2,6 scores were 5% or higher, and the study thus was not designed to assess the performance (eg, sensitivity, specificity, positive/negative predictive values) of PREMM 1, 2, 6 in this cohort. Our prior study 20 validating the performance of PREMM 1, 2, 6 in population-based patients with colorectal cancer found the 5% or higher score threshold to have more than 99% negative predictive value, although future studies will be needed to validate the performance of the patient self-administered version of PREMM 1,2,6 .
Another potential limitation was that PREMM 1,2,6 was not designed specifically to predict the presence of PMS2 or EPCAM mutations and thus we cannot account for the possibility that the model may have missed some such mutation carriers. The newly developed PREMM 5 model, which includes PMS2 and EPCAM prediction, hopefully will be a key tool in facilitating such systematic LS assessment in the future. 21 PREMM 1,2,6 does not account for MMR protein immunohistochemistry or microsatellite instability tumor testing results, and such data were not available for this study. Furthermore, the field of hereditary cancer risk assessment rapidly has adopted the use of multigene panel testing as an alternative to syndrome-specific genetic testing, and it is unclear how well PREMM 1,2,6 identifies individuals with other, non-LS forms of hereditary cancer risk.
Finally, we acknowledge that the systematic use of a patient self-administered version of PREMM 1,2,6 within a study protocol may not entirely mirror real-world clinical practice, thus potentially limiting the generalizability of this study. That said, the primary aim of this study was to implement and evaluate the feasibility of systematic LS risk assessment in a busy, communitybased setting, and these data provide strong proofof-principle that such processes can be integrated into routine clinical care effectively. For instance, even though 5 of 6 (83%) Lynch syndrome mutation carriers identified in this study had a personal history of CRC or endometrial cancer, only 1 of them was diagnosed with LS within 3 years of their cancer diagnosis, suggesting that the others would have continued to go undiagnosed if not for systematic risk assessment with PREMM 1, 2, 6 . These findings are a key step toward the goal of bringing routine LS risk assessment into preventive health care settings where the opportunity for genetically driven cancer prevention likely is highest, as opposed to the more common current scenario in which LS is diagnosed only after an individual is diagnosed with a MMR-deficient colorectal or endometrial cancer. We found that 2.1% of the 146 patients who underwent genetic testing during the study period carried a pathogenic MMR gene mutation that would impact their medical management. However, data on outcomes related to genetic testing such as impact on surveillance behaviors, uptake of prophylactic surgery, and communication to family members were beyond the scope of this study. Additional prospective, large-scale studies will be necessary to better determine the frequency of germline mutations among the general population and the impact of genetic testing and subsequent screening procedures for cancer prevention in newly identified gene mutation carriers with LS and at-risk relatives. Although most of the providers (81.8%) found that the family history of cancer information was helpful in making treatment decisions, regardless of whether the patient tested positive for LS, longitudinal studies will better quantify the impact of such an intervention on medical decision making pertaining to cancer screening and other cancer risk-reducing interventions.
In summary, this study showed that a carefully designed, systematic approach to LS risk assessment using PREMM 1,2,6 is feasible to identify at-risk individuals in a busy, community-based gastroenterology practice. Notably, more than 3000 patients were able to selfadminister PREMM 1,2,6 risk assessment with minimal guidance from providers in the practice and with little disruption to normal patient flow. As inherited cancer risk assessment and advances in the management, treatment, and chemoprevention continue to advance, this type of systematic approach can provide patients and their families with effective and life-saving preventive cancer care.
